,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Cabazitaxel,Acarbose,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora. Cabazitaxel does not interact with this pathway.",See Summary
1,Cabazitaxel,Acenocoumarol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolised by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Cabazitaxel does not inhibit or induce these CYPs.,See Summary
2,Cabazitaxel,Acetylsalicylic acid (Aspirin),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid and then further metabolised by glucuronidation (by several UGTs, major UGT1A6). Cabazitaxel does not inhibit or induce UGTs.",See Summary
3,Cabazitaxel,Agomelatine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2 (90%), with a small proportion metabolised by CYP2C9 and CYP2C19 (10%). Cabazitaxel does not inhibit or induce these CYPs.",See Summary
4,Cabazitaxel,Alendronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alendronate is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
5,Cabazitaxel,Alfentanil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of alfentanil. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with alfentanil. Therefore, no clinically relevant effect on alfentanil exposure is expected.",See Summary
6,Cabazitaxel,Alfuzosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolised by CYP3A. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of alfuzosin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with alfuzosin. Therefore, no clinically relevant effect on alfuzosin exposure is expected.",See Summary
7,Cabazitaxel,Aliskiren,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolised and is mainly excreted unchanged in faeces. Aliskiren is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of aliskiren. However, no clinically relevant effect on aliskiren exposure is expected.",See Summary
8,Cabazitaxel,Allopurinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Cabazitaxel does not interact with this metabolic pathway.,See Summary
9,Cabazitaxel,Alosetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that alosetron is metabolised by CYPs 2C9, 3A4 and 1A2. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase alosetron concentrations. However, no clinically relevant effect on alosetron exposure is expected.",See Summary
10,Cabazitaxel,Alprazolam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of alprazolam. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with alprazolam. Therefore, no clinically relevant effect on alprazolam exposure is expected.",See Summary
11,Cabazitaxel,Aluminium hydroxide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aluminium hydroxide is not metabolised. Cabazitaxel is unlikely to interfere with this metabolic pathway.,See Summary
12,Cabazitaxel,Ambrisentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is metabolized by glucuronidation via UGTs 1A3, 1A9 and 2B7 and to a lesser extent by CYP3A4 and CYP2C19. Ambrisentan is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase ambrisentan concentrations. However, no clinically relevant effect on ambrisentan exposure is expected.",See Summary
13,Cabazitaxel,Amikacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amikacin is eliminated by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
14,Cabazitaxel,Amiloride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged in the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
15,Cabazitaxel,Amiodarone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiodarone is metabolised by CYP3A4 and CYP2C8. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase amiodarone concentrations. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with amiodarone. Therefore, no clinically relevant effect on amiodarone exposure is expected. Moreover, the major metabolite of amiodarone, desethylamiodarone, is an inhibitor of CYPs 3A4 (weak), 2C9 (moderate), 2D6 (moderate), 2C19 (weak), 1A1 (strong) and 2B6 (moderate). Cabazitaxel concentrations may increase due to weak CYP3A4 inhibition, but this is unlikely to be clinically relevant.",See Summary
16,Cabazitaxel,Amisulpride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolised and is primarily renally eliminated (possibly via OCT). Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.,See Summary
17,Cabazitaxel,Amitriptyline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19, with a small proportion metabolised by CYPs 3A4, 1A2 and 2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase amitriptyline concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on amitriptyline exposure is expected.",See Summary
18,Cabazitaxel,Amlodipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of amlodipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with amlodipine. Therefore, no clinically relevant effect on amlodipine exposure is expected.",See Summary
19,Cabazitaxel,Amoxicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
20,Cabazitaxel,Amphotericin B,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Amphotericin B is not appreciably metabolised but is eliminated to a large extent in the bile. Cabazitaxel does not interfere with this elimination pathway. However, the European SPC for amphotericin states that concomitant use of amphotericin B and antineoplastic agents can increase the risk of renal toxicity, bronchospasm and hypotension. Monitoring may be required.",See Summary
21,Cabazitaxel,Ampicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. About 20-40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60-80% is excreted in the urine within 6 hours. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
22,Cabazitaxel,Anidulafungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperatures. Cabazitaxel does not interact with this metabolic pathway.,See Summary
23,Cabazitaxel,Antacids,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Antacids are not metabolised by CYPs. Cabazitaxel is unlikely to interfere with this metabolic pathway.,See Summary
24,Cabazitaxel,Apixaban,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is a substrate of P-gp and BCRP, and is metabolised by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8, 2C9 and 2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of apixaban. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with apixaban. Therefore, no clinically relevant effect on apixaban exposure is expected.",See Summary
25,Cabazitaxel,Aprepitant,"
No Interaction Expected
","
Very Low
","Coadministration has been studied and based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of aprepitant. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with aprepitant. Therefore, no clinically relevant effect on aprepitant exposure is expected. Furthermore, during treatment aprepitant is a moderate inhibitor of CYP3A4 and may increase cabazitaxel concentrations. After coadministration with aprepitant, no effect on cabazitaxel exposure was observed. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Cabazitaxel concentrations may decrease due to CYP3A4 induction, but this is not considered to be clinically relevant.",See Summary
26,Cabazitaxel,Aripiprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolised by CYP3A4 and CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of aripiprazole. However, no clinically relevant effect on aripiprazole exposure is expected.",See Summary
27,Cabazitaxel,Asenapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolised by glucuronidation (UGT1A4) and oxidative metabolism (CYPs 1A2 (major), 3A4 (minor) and 2D6 (minor)). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of asenapine. However, since CYP3A4 is a minor pathway, no clinically relevant effect on asenapine exposure is expected.",See Summary
28,Cabazitaxel,Astemizole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Astemizole is metabolised by CYPs 2D6, 2J2 and 3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of astemizole. However, no clinically relevant effect on astemizole exposure is expected.",See Summary
29,Cabazitaxel,Atenolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
30,Cabazitaxel,Atorvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atorvastatin is metabolised by CYP3A4 and is a substrate of P-gp and OATP1B1. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of atorvastatin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with atorvastatin. Therefore, no clinically relevant effect on atorvastatin exposure is expected.",See Summary
31,Cabazitaxel,Azathioprine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolised analogously to natural purines. Cabazitaxel does not interact with this pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
32,Cabazitaxel,Azithromycin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Azithromycin is mainly eliminated via biliary excretion; animal data suggest this may occur via P-gp and MRP2. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of azithromycin. However, no clinically relevant effect on azithromycin exposure is expected. Azithromycin is also an inhibitor of P-gp. Cabazitaxel is an in vitro substrate of P-gp and concentrations may increase due to P-gp inhibition. The clinical relevance of P-gp inhibition by azithromycin is unknown. Monitoring for cabazitaxel toxicity may be required.",See Summary
33,Cabazitaxel,Beclometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate. Cabazitaxel does not interact with this metabolic pathway.",See Summary
34,Cabazitaxel,Bedaquiline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bedaquiline is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of bedaquiline. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with bedaquiline. Therefore, no clinically relevant effect on bedaquiline exposure is expected.",See Summary
35,Cabazitaxel,Bendroflumethiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. Cabazitaxel is unlikely to interfere with this elimination pathway. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically significant interaction is unlikely in the range of observed clinical concentrations. Cabazitaxel is not transported by OATs.,See Summary
36,Cabazitaxel,Bepridil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bepridil is metabolised by CYP2D6 (major) and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of bepridil. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with bepridil. Therefore, no clinically relevant effect on bepridil exposure is expected.",See Summary
37,Cabazitaxel,Betamethasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betamethasone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of betamethasone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with betamethasone. Therefore, no clinically relevant effect on betamethasone exposure is expected.",See Summary
38,Cabazitaxel,Bezafibrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of a bezafibrate dose is eliminated unchanged in the urine. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1. Cabazitaxel is unlikely to interfere with pathway.,See Summary
39,Cabazitaxel,Bisacodyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Cabazitaxel does not interact with this metabolic pathway.,See Summary
40,Cabazitaxel,Bisoprolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolised by CYP3A4 and CYP2D6, and partly eliminated unchanged in the urine. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase bisoprolol concentrations. However, no clinically relevant effect on bisoprolol exposure is expected.",See Summary
41,Cabazitaxel,Bosentan,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Bosentan is a substrate of CYP3A4 and CYP2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase bosentan concentrations. However, no clinically relevant effect on bosentan exposure is expected. Bosentan is also a weak inducer of CYP3A4 and CYP2C9. Concentrations of cabazitaxel may decrease due to induction of CYP3A4. Imatinib concentrations, on average, decreased by 33% in the presence of bosentan in a phase III clinical study and a similar effect may be expected with cabazitaxel. If coadministered, closely monitor cabazitaxel efficacy.",See Summary
42,Cabazitaxel,Bromazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase bromazepam concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on bromazepam exposure is expected.",See Summary
43,Cabazitaxel,Budesonide,"
No Interaction Expected
","
Low
","Budesonide is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of budesonide. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with budesonide. Therefore, no clinically relevant effect on budesonide exposure is expected. Furthermore, after coadministration budesonide did not alter the mean AUC of cabazitaxel in the presence of prednisone.",See Summary
44,Cabazitaxel,Buprenorphine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of buprenorphine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with buprenorphine. Therefore, no clinically relevant effect on buprenorphine exposure is expected.",See Summary
45,Cabazitaxel,Bupropion,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolised by CYP2B6 and is a strong inhibitor of CYP2D6. Cabazitaxel does not interact with this pathway.,See Summary
46,Cabazitaxel,Buspirone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of buspirone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with buspirone. Therefore, no clinically relevant effect on buspirone exposure is expected.",See Summary
47,Cabazitaxel,Calcium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat. Cabazitaxel is unlikely to interfere with these elimination pathways.",See Summary
48,Cabazitaxel,Candesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
49,Cabazitaxel,Capreomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
50,Cabazitaxel,Captopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Cabazitaxel does not inhibit or induce OATs.,See Summary
51,Cabazitaxel,Carbamazepine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Carbamazepine is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of carbamazepine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with carbamazepine. Therefore, no clinically relevant effect on carbamazepine exposure is expected. Moreover, carbamazepine is an inducer of CYPs 2C8 (strong), 2C9 (strong), 3A4 (strong), 1A2 (weak), 2B6 and UGT1A1. Cabazitaxel concentrations may decrease due to strong CYP3A4 induction. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with carbamazepine. Care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
52,Cabazitaxel,Carvedilol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additional metabolism via CYP2D6 and to a lesser extent by CYPs 2C9 and 1A2. Cabazitaxel does not inhibit or induce these CYPs or UGTs.",See Summary
53,Cabazitaxel,Caspofungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non-CYP mediated pathway. Cabazitaxel does not interact with this metabolic pathway.,See Summary
54,Cabazitaxel,Cefalexin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly renally eliminated unchanged by glomerular filtration and tubular secretion via OAT1 and MATE1. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
55,Cabazitaxel,Cefazolin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
56,Cabazitaxel,Cefixime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
57,Cabazitaxel,Cefotaxime,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolised by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
58,Cabazitaxel,Ceftazidime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
59,Cabazitaxel,Ceftriaxone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
60,Cabazitaxel,Celecoxib,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolised by CYP2C9. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
61,Cabazitaxel,Cetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine is also an inhibitor of OCT2. Cabazitaxel does not interact with this pathway.,See Summary
62,Cabazitaxel,Chloramphenicol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Chloramphenicol is predominantly glucuronidated. Cabazitaxel does not inhibit or induce UGTs. In vitro studies have shown that chloramphenicol can inhibit metabolism mediated by CYPs 3A4 (strong), 2C19 (strong) and 2D6 (weak). Concentrations of cabazitaxel may increase due to CYP3A4 inhibition. As the clinical relevance of this interaction is unknown, monitoring for cabazitaxel toxicity may be required. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the absorbed concentrations are unlikely to cause a clinically significant interaction.",See Summary
63,Cabazitaxel,Chlordiazepoxide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolised by CYP3A4, but does not inhibit or induce cytochromes. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of chlordiazepoxide. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with chlordiazepoxide. Therefore, no clinically relevant effect on chlordiazepoxide exposure is expected.",See Summary
64,Cabazitaxel,Chlorphenamine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolised in the liver via CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
65,Cabazitaxel,Chlorpromazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolised mainly by CYP2D6, but also by CYP1A2. Cabazitaxel does not inhibit or induce CYP2D6 or CYP1A2.",See Summary
66,Cabazitaxel,Chlortalidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
67,Cabazitaxel,Ciclosporin (Cyclosporine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclosporin is a substrate of CYP3A4 and P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of ciclosporin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ciclosporin. Therefore, no clinically relevant effect on ciclosporin exposure is expected. Ciclosporin is also an inhibitor of CYP3A4 and OATP1B1. Cabazitaxel concentrations may increase due to CYP3A4 inhibition, but this is unlikely to be clinically relevant. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur after coadministration with ciclosporin.",See Summary
68,Cabazitaxel,Cilazapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
69,Cabazitaxel,Cimetidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cimetidine is metabolised by CYP450 enzymes. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase cimetidine concentrations. However, no clinically relevant effect on cimetidine exposure is expected. In vitro data indicate that cimetidine inhibits OAT1 and OCT2 but at concentrations much higher than the observed clinical concentrations. Cimetidine is also a weak inhibitor of CYPs 3A4, 1A2, 2D6 and 2C19. Cabazitaxel concentrations may increase due to CYP3A4 inhibition, but this is unlikely to be clinically relevant.",See Summary
70,Cabazitaxel,Ciprofloxacin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged in the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolised and partially cleared through the bile and intestine. Cabazitaxel is unlikely to interfere with this elimination pathway. Ciprofloxacin is a weak to moderate inhibitor of CYP3A4 and a strong inhibitor of CYP1A2. Concentrations of cabazitaxel may increase due to CYP3A4 inhibition, but this is unlikely to be clinically relevant. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur with ciprofloxacin.",See Summary
71,Cabazitaxel,Cisapride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisapride is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of cisapride. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with cisapride. Therefore, no clinically relevant effect on cisapride exposure is expected.",See Summary
72,Cabazitaxel,Citalopram,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolised by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of citalopram. However, since CYP3A4 is a minor pathway, no clinically relevant effect on citalopram exposure is expected.",See Summary
73,Cabazitaxel,Clarithromycin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Clarithromycin is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of clarithromycin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with clarithromycin. Therefore, no clinically relevant effect on clarithromycin exposure is expected. Clarithromycin is also an inhibitor of CYP3A4 (strong) and P-gp and may increase cabazitaxel concentrations. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur with clarithromycin. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
74,Cabazitaxel,Clavulanic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolised (likely non-CYP mediated pathway) and excreted in the urine by glomerular filtration. Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.,See Summary
75,Cabazitaxel,Clemastine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clemastine is predominantly metabolised in the liver via CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
76,Cabazitaxel,Clindamycin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of clindamycin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with clindamycin. Therefore, no clinically relevant effect on clindamycin exposure is expected. In vitro data suggest that clindamycin is a CYP3A4 inhibitor and may increase concentrations of cabazitaxel, but this is unlikely to be clinically significant.",See Summary
77,Cabazitaxel,Clobetasol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of clobetasol.,See Summary
78,Cabazitaxel,Clofazimine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces. Cabazitaxel is unlikely to interfere with this elimination pathway. Furthermore, in vitro data suggest that clofazimine is a CYP3A4 inhibitor and may increase concentrations of cabazitaxel. However, this is unlikely to be clinically relevant.",See Summary
79,Cabazitaxel,Clofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolysed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Cabazitaxel does not interact with this metabolic or elimination pathway.",See Summary
80,Cabazitaxel,Clomipramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolised by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Clomipramine and desmethylclomipramine are both metabolised by CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of clomipramine. However, no clinically relevant effect on clomipramine exposure is expected.",See Summary
81,Cabazitaxel,Clonidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in the form of the unchanged parent drug (40-60% of the dose). Clonidine is also a weak inhibitor of OCT2. Cabazitaxel is unlikely to interfere with this pathway.",See Summary
82,Cabazitaxel,Clopidogrel,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug and is converted to its active metabolite mainly through CYP2C19 with CYPs 3A4, 2B6 and 1A2 playing a minor role. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase clopidogrel concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on clopidogrel exposure is expected. Moreover, clopidogrel is an inhibitor of CYP2C8 (strong), CYP2B6 (weak) and of CYP2C9 (in vitro) at high concentrations. The clinical relevance of CYP2C9 inhibition is unknown. Cabazitaxel does not interact with this pathway.",See Summary
83,Cabazitaxel,Clorazepate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolised to oxazepam by CYP3A4. Oxazepam is mainly glucuronidated. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nordiazepam. However, no clinically relevant effect on nordiazepam exposure is expected.",See Summary
84,Cabazitaxel,Cloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
85,Cabazitaxel,Clozapine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clozapine is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase clozapine concentrations, but no clinically relevant effect on clozapine exposure is expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
86,Cabazitaxel,Codeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine is converted via CYP2D6 to morphine, an active metabolite with analgesic and opioid properties. Morphine is further metabolized by conjugation with glucuronic acid to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active). Codeine is converted via CYP3A4 to norcodeine, an inactive metabolite. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of codeine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with codeine. Additionally, the metabolite morphine is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of morphine. No clinically relevant effect on codeine and morphine exposure is expected.",See Summary
87,Cabazitaxel,Colchicine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is metabolised by CYP3A4 and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of colchicine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with colchicine. Therefore, no clinically relevant effect on colchicine exposure is expected.",See Summary
88,Cabazitaxel,Cycloserine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly renally excreted via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
89,Cabazitaxel,Dabigatran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is transported via P-gp and is renally excreted. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of dabigatran. However, no clinically relevant effect on dabigatran exposure is expected.",See Summary
90,Cabazitaxel,Dalteparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
91,Cabazitaxel,Dapsone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP450 enzymes. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase dapsone concentrations. However, this is unlikely to be clinically relevant.",See Summary
92,Cabazitaxel,Desipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
93,Cabazitaxel,Desogestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of etonogestrel. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with etonogestrel. Therefore, no clinically relevant effect on etonogestrel exposure is expected.",See Summary
94,Cabazitaxel,Dexamethasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexamethasone is a substrate of CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of dexamethasone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with dexamethasone. Therefore, no clinically relevant effect on dexamethasone exposure is expected. Dexamethasone has also been described as a weak inducer of CYP3A4 and could possibly decrease cabazitaxel plasma concentrations. The clinical relevance of this interaction is unknown as the induction of CYP3A4 by dexamethasone has not yet been established. A clinically relevant interaction is unlikely.",See Summary
95,Cabazitaxel,Dextropropoxyphene,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of dextropropoxyphene. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with dextropropoxyphene. Therefore, no clinically relevant effect on dextropropoxyphene exposure is expected.",See Summary
96,Cabazitaxel,Diamorphine (diacetylmorphine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolised by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of morphine. However, no clinically relevant effect on morphine exposure is expected.",See Summary
97,Cabazitaxel,Diazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolised to nordiazepam (by CYP3A4 and CYP2C19) and to temazepam (mainly by CYP3A4). Temazepam is mainly glucuronidated. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nordiazepam and temazepam. However, no clinically relevant effect on nordiazepam and temazepam exposure is expected.",See Summary
98,Cabazitaxel,Diclofenac,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidised by CYP2C9. Cabazitaxel does not inhibit or induce UGTs or CYP2C9.,See Summary
99,Cabazitaxel,Digoxin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is renally eliminated via OATP4C1 and P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of digoxin. However, no clinically relevant effect on digoxin exposure is expected.",See Summary
100,Cabazitaxel,Dihydrocodeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of dihydrocodeine. However, since CYP3A4 is a minor pathway, no clinically relevant effect on dihydrocodeine exposure is expected.",See Summary
101,Cabazitaxel,Diltiazem,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diltiazem is metabolised by CYP3A4 and CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase diltiazem concentrations. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with diltiazem. Therefore, no clinically relevant effect on diltiazem exposure is expected. Diltiazem is also a moderate inhibitor of CYP3A4, but a clinically relevant effect on cabazitaxel exposure is not expected. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur after coadministration with diltiazem.",See Summary
102,Cabazitaxel,Diphenhydramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 1A2, 2C9 and 2C19. Diphenhydramine is also a weak inhibitor of CYP2D6. Cabazitaxel does not interact with this pathway.",See Summary
103,Cabazitaxel,Dipyridamole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Cabazitaxel does not inhibit or induce UGTs.",See Summary
104,Cabazitaxel,Disopyramide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is metabolised by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of disopyramide. However, since CYP3A4 is a minor pathway, no clinically relevant effect on disopyramide exposure is expected.",See Summary
105,Cabazitaxel,Dolasetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolised by CYP2D6 (10-20%) and CYP3A4 (<1%). Cabazitaxel is an in vitro inhibitor of CYP3A4. However, since CYP3A4 is a minor pathway, no clinically significant effect on dolasetron exposure is expected.",See Summary
106,Cabazitaxel,Domperidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Domperidone is mainly metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of domperidone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with domperidone. Therefore, no clinically relevant effect on domperidone exposure is expected.",See Summary
107,Cabazitaxel,Dopamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect disposition of cabazitaxel, or to be affected if coadministered with cabazitaxel.",See Summary
108,Cabazitaxel,Doxazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolised mainly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of doxazosin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with doxazosin. Therefore, no clinically relevant effect on doxazosin exposure is expected.",See Summary
109,Cabazitaxel,Doxepin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolised to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Doxepin and nordoxepin are both metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2C19 or CYP2D6.,See Summary
110,Cabazitaxel,Doxycycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40-60% of an administered dose can be accounted for in the urine. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
111,Cabazitaxel,Dronabinol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolised by CYP2C9 and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase dronabinol concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on dronabinol exposure is expected.",See Summary
112,Cabazitaxel,Drospirenone,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolised to a minor extent via CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase drospirenone concentrations. However, no clinically relevant effect on drospirenone exposure is expected.",See Summary
113,Cabazitaxel,Dulaglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is degraded by endogenous endopeptidases. Cabazitaxel does not interact with this metabolic pathway.,See Summary
114,Cabazitaxel,Duloxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolised by CYP2D6 and CYP1A2. Cabazitaxel does not inhibit or induce CYP2D6 or CYP1A2.,See Summary
115,Cabazitaxel,Dutasteride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of dutasteride. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with dutasteride. Therefore, no clinically relevant effect on dutasteride exposure is expected.",See Summary
116,Cabazitaxel,Dydrogesterone,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolised to dihydrodydrogesterone (possibly via CYP3A4). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase dydrogesterone concentrations. However, no clinically relevant effect on dydrogesterone exposure is expected.",See Summary
117,Cabazitaxel,Edoxaban,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is partially metabolised by CYP3A4 (<10%) and is transported via P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase edoxaban concentrations. However, no clinically relevant effect on edoxaban exposure is expected.",See Summary
118,Cabazitaxel,Eltrombopag,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (via UGT1A1 and UGT1A3) and oxidation (via CYP1A2 and CYP2C8). Cabazitaxel does not inhibit or induce these CYPs or UGTs.,See Summary
119,Cabazitaxel,Enalapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is renally eliminated (possibly via OATs). Cabazitaxel is unlikely to interfere with this elimination pathway. ,See Summary
120,Cabazitaxel,Enoxaparin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is predominantly renally excreted. Cabazitaxel is unlikely to interact with this metabolic or elimination pathway.",See Summary
121,Cabazitaxel,Eprosartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eprosartan is largely excreted in bile and urine as unchanged drug. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
122,Cabazitaxel,Ertapenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
123,Cabazitaxel,Erythromycin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Erythromycin is a substrate of CYP3A4 and P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of erythromycin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with erythromycin. Therefore, no clinically relevant effect on erythromycin exposure is expected. Erythromycin is an inhibitor of CYP3A4 (moderate) and P-gp. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur after coadministration with erythromycin. Cabazitaxel is also an in vitro substrate of P-gp and concentrations may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. Monitoring for cabazitaxel toxicity may be required.",See Summary
124,Cabazitaxel,Escitalopram,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolised by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of escitalopram. However, since CYP3A4 is a minor pathway no clinically relevant effect on escitalopram exposure is expected.",See Summary
125,Cabazitaxel,Esomeprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is metabolised by CYP2C19 and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase esomeprazole concentrations. However, no clinically relevant effect on esomeprazole exposure is expected. Esomeprazole is also an inhibitor of CYP2C19. Cabazitaxel is not metabolised by CYP2C19.",See Summary
126,Cabazitaxel,Estazolam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolised to its major metabolite 4-hydroxyestazolam via CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of estazolam. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with estazolam. Therefore, no clinically relevant effect on estazolam exposure is expected.",See Summary
127,Cabazitaxel,Estradiol,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolised by CYP3A4, CYP1A2 and is glucuronidated. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase estradiol concentrations. However, no clinically relevant effect on estradiol exposure is expected.",See Summary
128,Cabazitaxel,Ethambutol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolised by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%). Cabazitaxel does not interact with this metabolic or elimination pathway.,See Summary
129,Cabazitaxel,Ethinylestradiol,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethinylestradiol undergoes oxidation (CYP3A4>CYP2C9), sulfation and glucuronidation (UGT1A1). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase ethinylestradiol concentrations. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ethinylestradiol. Therefore, no clinically relevant effect on ethinylestradiol exposure is expected.",See Summary
130,Cabazitaxel,Ethionamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolised in the liver; animal studies suggest involvement of flavin-containing monooxygenases. Cabazitaxel does not interact with this metabolic pathway.,See Summary
131,Cabazitaxel,Etonogestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of etonogestrel. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with etonogestrel. Therefore, no clinically relevant effect on etonogestrel exposure is expected.",See Summary
132,Cabazitaxel,Everolimus (Immunosuppressant),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Everolimus is mainly metabolised by CYP3A4 and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of everolimus. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with everolimus. Therefore, no clinically relevant effect on everolimus exposure is expected. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
133,Cabazitaxel,Exenatide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exenatide is cleared mainly by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
134,Cabazitaxel,Ezetimibe,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Cabazitaxel does not inhibit or induce UGTs.,See Summary
135,Cabazitaxel,Famotidine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is excreted via OAT1/OAT3. Cabazitaxel does not inhibit or induce OATs.,See Summary
136,Cabazitaxel,Felodipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of felodipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with felodipine. Therefore, no clinically relevant effect on felodipine exposure is expected.",See Summary
137,Cabazitaxel,Fenofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolysed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. Cabazitaxel does not interact with this pathway.",See Summary
138,Cabazitaxel,Fentanyl,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of fentanyl. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with fentanyl. Therefore, no clinically relevant effect on fentanyl exposure is expected.",See Summary
139,Cabazitaxel,Fexofenadine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of fexofenadine. However, no clinically relevant effect on fexofenadine exposure is expected.",See Summary
140,Cabazitaxel,Finasteride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of finasteride. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with finasteride. Therefore, no clinically relevant effect on finasteride exposure is expected.",See Summary
141,Cabazitaxel,Fish oils,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
142,Cabazitaxel,Flecainide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolised mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also renally eliminated unchanged. Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.",See Summary
143,Cabazitaxel,Flucloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly renally eliminated partly by glomerular filtration and partly by active secretion via OAT1. Cabazitaxel is unlikely to interfere with this elimination pathway. Flucloxacillin has been described as a CYP3A4 inducer and may decrease cabazitaxel exposure. However, the mechanism of this interaction is unknown but is unlikely to be clinically relevant.",See Summary
144,Cabazitaxel,Fluconazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is cleared primarily by renal excretion and is also an inhibitor of CYPs 3A4 (moderate), 2C9 (moderate) and 2C19 (strong). Concentrations of cabazitaxel may increase due to CYP3A4 inhibition, but this is unlikely to be clinically relevant. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur after coadministration with fluconazole.",See Summary
145,Cabazitaxel,Flucytosine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil (5-FU). 5-FU is further metabolised by dihydropyrimidine dehydrogenase to an inactive metabolite. Cabazitaxel does not interfere with this elimination pathway. However, 5-FU binds to the enzyme thymidylate synthase resulting in DNA damage. This mechanism occurs in all fast dividing cells including bone marrow cells, resulting in haematological toxicity. Cabazitaxel also induces haematological toxicity which could be enhanced by the use of flucytosine. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
146,Cabazitaxel,Fludrocortisone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolised in the liver to inactive metabolites, possibly via CYP3A. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase fludrocortisone concentrations. However, no clinically relevant effect on fludrocortisone exposure is expected.",See Summary
147,Cabazitaxel,Flunitrazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolised mainly via CYP3A4 and CYP2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase flunitrazepam concentrations. However, no clinically relevant effect on flunitrazepam exposure is expected.",See Summary
148,Cabazitaxel,Fluoxetine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is mainly metabolised by CYP2D6 and CYP2C9 and to a lesser extent by CYP2C19 and CYP3A4 to form norfluoxetine. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of fluoxetine. However, since CYP3A4 is a minor pathway, no clinically relevant effect on fluoxetine exposure is expected. Fluoxetine is also a strong inhibitor of CYP2D6 and CYP2C19. Cabazitaxel is not metabolised by these CYPs.",See Summary
149,Cabazitaxel,Fluphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
150,Cabazitaxel,Flurazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase flurazepam concentrations. However, no clinically relevant effect on flurazepam exposure is expected.",See Summary
151,Cabazitaxel,Fluticasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of fluticasone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with fluticasone. Therefore, no clinically relevant effect on fluticasone exposure is expected.",See Summary
152,Cabazitaxel,Fluvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolised by CYP2C9 (75%) and to a lesser extent by CYP3A4 (20%) and CYP2C8 (5%). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase fluvastatin concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on fluvastatin exposure is expected. Moreover, fluvastatin potentially inhibits CYP2C9, but the clinical relevance of CYP2C9 inhibition is unknown. Cabazitaxel is not metabolised by CYP2C9.",See Summary
153,Cabazitaxel,Fluvoxamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Cabazitaxel does not inhibit or induce CYP2D6 or CYP1A2. Fluvoxamine is also an inhibitor of CYPs 1A2 (strong), 2C19 (strong), 3A4 (moderate), 2C9 (weak-moderate) and 2D6 (weak). Concentrations of cabazitaxel may increase due to CYP3A4 inhibition, but this is unlikely to be clinically relevant. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur after coadministration with fluvoxamine.",See Summary
154,Cabazitaxel,Fondaparinux,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is predominantly renally eliminated. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
155,Cabazitaxel,Formoterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation. As multiple CYP450 and UGT enzymes catalyse the transformation the potential for a pharmacokinetic interaction is low. Additionally, cabazitaxel does not inhibit or induce these CYPs or UGTs.",See Summary
156,Cabazitaxel,Fosaprepitant,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fosaprepitant is rapidly, almost completely, converted to the active metabolite aprepitant. Cabazitaxel does not interact with this metabolic pathway. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of aprepitant. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with aprepitant. Therefore, no clinically relevant effect on aprepitant exposure is expected. Furthermore, during treatment aprepitant is a moderate inhibitor of CYP3A4 and may increase cabazitaxel concentrations. After coadministration with aprepitant, no effect on cabazitaxel exposure was observed. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Cabazitaxel concentrations may decrease due to CYP3A4 induction, but this is not considered to be clinically relevant.",See Summary
157,Cabazitaxel,Fosphenytoin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Fosphenytoin is rapidly converted to the active metabolite phenytoin. Cabazitaxel does not interact with this metabolic pathway. Phenytoin is mainly metabolized by CYP2C9 and to a lesser extent by CYP2C19. Cabazitaxel does not inhibit or induce CYP2C9 or CYP2C19. Furthermore, phenytoin is a strong inducer of CYP3A4, UGT and P-gp. Cabazitaxel concentrations may decrease due to CYP3A4 and P-gp induction. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with fosphenytoin. Therefore, care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
158,Cabazitaxel,Furosemide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also renally eliminated unchanged (via OATs). OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. In vitro data indicate that furosemide is also an inhibitor of OAT1/3. Cabazitaxel does not interact with this pathway.,See Summary
159,Cabazitaxel,Gabapentin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
160,Cabazitaxel,Gemfibrozil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Gemfibrozil is also an inhibitor of CYP2C8 (strong), OATP1B1 and OAT3. In vitro data indicate gemfibrozil to be a strong inhibitor of CYP2C9 but in vivo data showed no clinically relevant effect on CYP2C9. Cabazitaxel does not interact with this pathway. ",See Summary
161,Cabazitaxel,Gentamicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
162,Cabazitaxel,Gestodene,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of gestodene. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with gestodene. Therefore, no clinically relevant effect on gestodene exposure is expected.",See Summary
163,Cabazitaxel,Glibenclamide (Glyburide),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of glibenclamide. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with glibenclamide. Therefore, no clinically relevant effect on glibenclamide exposure is expected.",See Summary
164,Cabazitaxel,Gliclazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C19. Cabazitaxel does not inhibit or induce CYP2C9 or CYP2C19.,See Summary
165,Cabazitaxel,Glimepiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is mainly metabolised by CYP2C9. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
166,Cabazitaxel,Glipizide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolised by CYP2C9. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
167,Cabazitaxel,Granisetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Granisetron is metabolised by CYP3A4 and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of granisetron. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with granisetron. Therefore, no clinically relevant effect on granisetron exposure is expected.",See Summary
168,Cabazitaxel,Grapefruit juice,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Grapefruit juice is known to inhibit CYP3A4 enzymes and may increase cabazitaxel concentrations. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with grapefruit juice. If coadministration is clinically necessary, monitor closely for cabazitaxel toxicity.",See Summary
169,Cabazitaxel,Green tea,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
170,Cabazitaxel,Griseofulvin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. Cabazitaxel is unlikely to interfere with this elimination pathway. Griseofulvin is also a liver microsomal enzyme inducer and may lower plasma levels, and therefore reduce the efficacy of concomitantly administered medicinal products that are metabolised by CYP3A4, such as cabazitaxel. However, this is unlikely to be clinically relevant.",See Summary
171,Cabazitaxel,Haloperidol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGTs 2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4 and CYP2D6). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of haloperidol. However, no clinically relevant effect on haloperidol exposure is expected.",See Summary
172,Cabazitaxel,Heparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. Cabazitaxel does not interact with this metabolic pathway.,See Summary
173,Cabazitaxel,Hydralazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Cabazitaxel does not interact with this metabolic pathway. In vitro studies have suggested that hydralazine is a mixed enzyme inhibitor, which may weakly inhibit CYP3A4 and CYP2D6. Concentrations of cabazitaxel may increase due to weak CYP3A4 inhibition, but this is unlikely to be clinically relevant.",See Summary
174,Cabazitaxel,Hydrochlorothiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised but is cleared by the kidneys via OAT1. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Cabazitaxel does not inhibit or induce OATs.,See Summary
175,Cabazitaxel,Hydrocodone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of hydrocodone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with hydrocodone. Therefore, no clinically relevant effect on hydrocodone exposure is expected.",See Summary
176,Cabazitaxel,Hydrocortisone (oral),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of hydrocortisone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with hydrocortisone. Therefore, no clinically relevant effect on hydrocortisone exposure is expected.",See Summary
177,Cabazitaxel,Hydrocortisone (topical),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of hydrocortisone. ,See Summary
178,Cabazitaxel,Hydromorphone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Cabazitaxel does not inhibit or induce UGTs.",See Summary
179,Cabazitaxel,Hydroxyurea (Hydroxycarbamide),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyurea is metabolised in the liver and cleared via the lungs and kidneys. Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
180,Cabazitaxel,Hydroxyzine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolised by alcohol dehydrogenase and partly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase hydroxyzine concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on hydroxyzine exposure is expected.",See Summary
181,Cabazitaxel,Ibandronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibandronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
182,Cabazitaxel,Ibuprofen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Cabazitaxel does not inhibit or induce CYP2C9, CYP2C8 or UGTs.",See Summary
183,Cabazitaxel,Iloperidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of iloperidone. However, no clinically relevant effect on iloperidone exposure is expected.",See Summary
184,Cabazitaxel,Imipenem/Cilastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and to a lesser extent by active tubular secretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
185,Cabazitaxel,Imipramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolised by CYPs 3A4, 2C19 and 1A2 to desipramine. Imipramine and desipramine are both metabolised by CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of imipramine. However, no clinically relevant effect on imipramine exposure is expected.",See Summary
186,Cabazitaxel,Indapamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolised by CYP450s. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase indapamide concentrations. However, no clinically relevant effect on indapamide exposure is expected.",See Summary
187,Cabazitaxel,Insulin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
188,Cabazitaxel,Interferon alpha,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
189,Cabazitaxel,Interleukin 2 (Aldesleukin),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
190,Cabazitaxel,Ipratropium bromide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. Cabazitaxel does not interact with this metabolic pathway.,See Summary
191,Cabazitaxel,Irbesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolised by glucuronidation and oxidation (mainly CYP2C9). Cabazitaxel does not inhibit or induce CYP2C9 or UGTs.,See Summary
192,Cabazitaxel,Iron supplements,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
193,Cabazitaxel,Isoniazid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Cabazitaxel does not interact with this metabolic pathway.,See Summary
194,Cabazitaxel,Isosorbide dinitrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of isosorbide dinitrate. However, no clinically relevant effect on isosorbide dinitrate exposure is expected.",See Summary
195,Cabazitaxel,Itraconazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied care should be taken. Itraconazole is primarily metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of itraconazole. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with itraconazole. Therefore, no clinically relevant effect on itraconazole exposure is expected. Itraconazole is also an inhibitor of CYP3A4 (strong), CYP2C9 (weak), P-gp and BCRP. Cabazitaxel concentrations may increase due to strong CYP3A4 inhibition. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with itraconazole. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
196,Cabazitaxel,Ivabradine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of ivabradine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ivabradine. Therefore, no clinically relevant effect on ivabradine exposure is expected.",See Summary
197,Cabazitaxel,Kanamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
198,Cabazitaxel,Ketoconazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has been studied and care should be taken. Ketoconazole is a substrate of CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of ketoconazole. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ketoconazole. Therefore, no clinically relevant effect on ketoconazole exposure is expected. Moreover, ketoconazole is an inhibitor of CYP3A4 (strong) and P-gp. After coadministration with ketoconazole, cabazitaxel exposure was increased by 25%. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
199,Cabazitaxel,Labetalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated (via UGT1A1 and UGT2B7). Cabazitaxel does not inhibit or induce UGTs.,See Summary
200,Cabazitaxel,Lacidipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of lacidipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with lacidipine. Therefore, no clinically relevant effect on lacidipine exposure is expected.",See Summary
201,Cabazitaxel,Lactulose,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. Cabazitaxel does not interact with this metabolic pathway.,See Summary
202,Cabazitaxel,Lansoprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase lansoprazole concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on lansoprazole exposure is expected.",See Summary
203,Cabazitaxel,Lercanidipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of lercanidipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with lercanidipine. Therefore, no clinically relevant effect on lercanidipine exposure is expected.",See Summary
204,Cabazitaxel,Levocetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.,See Summary
205,Cabazitaxel,Levofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levofloxacin is renally eliminated mainly by glomerular filtration and active secretion (possibly OCT2). Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
206,Cabazitaxel,Levomepromazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
207,Cabazitaxel,Levonorgestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of levonorgestrel. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with levonorgestrel. Therefore, no clinically relevant effect on levonorgestrel exposure is expected.",See Summary
208,Cabazitaxel,Levonorgestrel (Emergency Contraception),"
Potential Interaction
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. However, the use of levonorgestrel as emergency contraception is a relative contraindication due to the risk of a pregnancy while having a hormone sensitive tumour. Therefore, the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of levonorgestrel. Coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with levonorgestrel. Therefore, no clinically relevant effect on levonorgestrel exposure is expected.",See Summary
209,Cabazitaxel,Levothyroxine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolised by deiodination (by enzymes of deiodinase family) and glucuronidation. Cabazitaxel does not interact with this metabolic pathway.,See Summary
210,Cabazitaxel,Lidocaine (Lignocaine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of lidocaine. However, since CYP3A4 is a minor pathway, no clinically relevant effect on lidocaine exposure is expected.",See Summary
211,Cabazitaxel,Linagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor elimination pathway. Linagliptin is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of linagliptin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with linagliptin. Therefore, no clinically relevant effect on linagliptin exposure is expected. Furthermore, linagliptin is a weak inhibitor of CYP3A4 and may increase cabazitaxel concentrations, but this is unlikely to be clinically relevant.",See Summary
212,Cabazitaxel,Linezolid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism. Cabazitaxel does not interact with this metabolic pathway.,See Summary
213,Cabazitaxel,Liraglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Liraglutide is degraded by endogenous endopeptidases. Cabazitaxel does not interact with this metabolic pathway.,See Summary
214,Cabazitaxel,Lisinopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is renally eliminated unchanged via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
215,Cabazitaxel,Lithium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate. Therefore, no pharmacokinetic interaction is expected. ",See Summary
216,Cabazitaxel,Live vaccines,"
Do Not Coadminister
","
Very Low
","Coadministration of live vaccines (such as BCG vaccine; measles, mumps and rubella vaccines; varicella vaccines; typhoid vaccines; rotavirus vaccines; yellow fever vaccines; oral polio vaccine) has not been studied. In patients, who are receiving cytotoxics or other immunosuppressant drugs, use of live vaccines for immunisation is contraindicated. If coadministration is judged clinically necessary, use with extreme caution since generalised infections can occur.",See Summary
217,Cabazitaxel,Loperamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolised by CYP3A4 and CYP2C8, and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase loperamide concentrations. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with loperamide. Therefore, no clinically relevant effect on loperamide exposure is expected.",See Summary
218,Cabazitaxel,Loratadine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of loratadine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with loratadine. Therefore, no clinically relevant effect on loratadine exposure is expected.",See Summary
219,Cabazitaxel,Lorazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam undergoes non-CYP mediated elimination. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
220,Cabazitaxel,Lormetazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated. Cabazitaxel does not inhibit or induce UGTs.,See Summary
221,Cabazitaxel,Losartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
222,Cabazitaxel,Lovastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of lovastatin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with lovastatin. Therefore, no clinically relevant effect on lovastatin exposure is expected.",See Summary
223,Cabazitaxel,Macitentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of macitentan. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with macitentan. Therefore, no clinically relevant effect on macitentan exposure is expected.",See Summary
224,Cabazitaxel,Magnesium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
225,Cabazitaxel,Maprotiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
226,Cabazitaxel,Medroxyprogesterone (depot),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of medroxyprogesterone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with medroxyprogesterone. Therefore, no clinically relevant effect on medroxyprogesterone exposure is expected.",See Summary
227,Cabazitaxel,Medroxyprogesterone (non-depot),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of medroxyprogesterone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with medroxyprogesterone. Therefore, no clinically relevant effect on medroxyprogesterone exposure is expected.",See Summary
228,Cabazitaxel,Mefenamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolised by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9. Cabazitaxel does not inhibit or induce CYP2C9 or UGTs.,See Summary
229,Cabazitaxel,Megestrol acetate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
230,Cabazitaxel,Meropenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney with in vitro data suggesting it is a substrate of the renal transporters OAT3>OAT1. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
231,Cabazitaxel,Mesalazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolised to N-acetyl-mesalazine by N-acetyltransferase. Cabazitaxel does not interact with this metabolic pathway.,See Summary
232,Cabazitaxel,Metamizole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metamizole is metabolised by hydrolysis to the active metabolite MAA in the gastrointestinal tract. Metamizole is metabolised in serum and excreted via urine (90%) and faeces (10%). Cabazitaxel does not interact with this metabolic pathway. Metamizole is also an inducer of CYP3A4 and may decrease cabazitaxel exposure. However, this is unlikely to be clinically relevant. ",See Summary
233,Cabazitaxel,Metformin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine and is a substrate of OCT1/2/3, MATE1 and MATE2K. Cabazitaxel does not inhibit or induce OCTs or MATEs.",See Summary
234,Cabazitaxel,Methadone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methadone is demethylated by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of methadone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with methadone. Therefore, no clinically relevant effect on methadone exposure is expected.",See Summary
235,Cabazitaxel,Methyldopa,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
236,Cabazitaxel,Methylphenidate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolised by CYP450s to a clinically relevant extent and does not inhibit or induce CYP450s. Therefore, there is little potential for methylphenidate to affect disposition of cabazitaxel, or to be affected if coadministered with cabazitaxel.",See Summary
237,Cabazitaxel,Methylprednisolone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of methylprednisolone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with methylprednisolone. Therefore, no clinically relevant effect on methylprednisolone exposure is expected.",See Summary
238,Cabazitaxel,Metoclopramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolised by the CYP450 system (mainly CYP2D6). Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
239,Cabazitaxel,Metolazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
240,Cabazitaxel,Metoprolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
241,Cabazitaxel,Metronidazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metronidazole is eliminated via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway. Moreover, elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, ciclosporin) with metronidazole. However, metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Therefore, no clinically relevant effect on cabazitaxel exposure is expected.",See Summary
242,Cabazitaxel,Mexiletine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Cabazitaxel does not inhibit or induce CYP2D6 or CYP1A2.,See Summary
243,Cabazitaxel,Mianserin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolised by CYP2D6 and CYP1A2, and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of mianserin. However, since CYP3A4 is a minor pathway, no clinically relevant effect on mianserin exposure is expected.",See Summary
244,Cabazitaxel,Miconazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Miconazole is extensively metabolized by the liver. Cabazitaxel is unlikely to interfere with this unspecified metabolic pathway. Miconazole is also an inhibitor of CYP2C9 (moderate) and CYP3A4 (strong). Cabazitaxel concentrations may increase due to strong CYP3A4 inhibition. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with miconazole. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required. Note: after dermal application miconazole is only minimally absorbed. Therefore, no clinical relevant interaction is expected.",See Summary
245,Cabazitaxel,Midazolam (oral),"
No Interaction Expected
","
Very Low
","Midazolam is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of midazolam. However, coadministration of cabazitaxel with midazolam did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%).",See Summary
246,Cabazitaxel,Midazolam (parenteral),"
No Interaction Expected
","
Very Low
","Midazolam is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of midazolam. However, coadministration of cabazitaxel with midazolam did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%).",See Summary
247,Cabazitaxel,Milnacipran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Cabazitaxel is unlikely to interact with this metabolic or elimination pathway.",See Summary
248,Cabazitaxel,Mirtazapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of mirtazapine. However, no clinically relevant effect on mirtazapine exposure is expected.",See Summary
249,Cabazitaxel,Mometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of mometasone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with mometasone. Therefore, no clinically relevant effect on mometasone exposure is expected. Note: No clinically relevant interaction are expected with the topical use of mometasone.",See Summary
250,Cabazitaxel,Montelukast,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolised by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase montelukast concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on montelukast exposure is expected.",See Summary
251,Cabazitaxel,Morphine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Additionally, morphine is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of morphine. However, no clinically relevant effect on morphine exposure is expected.",See Summary
252,Cabazitaxel,Moxifloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Cabazitaxel does not inhibit or induce UGTs.,See Summary
253,Cabazitaxel,Mycophenolate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. The active metabolite of mycophenolate, mycophenolic acid, is an inhibitor of OAT1/OAT3. Cabazitaxel does not inhibit or induce UGTs and is not transported by OATs. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
254,Cabazitaxel,Nadroparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nadroparin is renally excreted by a nonsaturable mechanism. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
255,Cabazitaxel,Nandrolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nandrolone is metabolised in the liver by alpha-reductase. Cabazitaxel does not interact with this metabolic pathway.,See Summary
256,Cabazitaxel,Naproxen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Cabazitaxel does not inhibit or induce CYP2C9, CYP1A2 or UGTs.",See Summary
257,Cabazitaxel,Nateglinide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolised by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase nateglinide concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on nateglinide exposure is expected.",See Summary
258,Cabazitaxel,Nebivolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
259,Cabazitaxel,Nefazodone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Nefazodone is metabolised mainly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nefazodone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with nefazodone. Therefore, no clinically relevant effect on nefazodone exposure is expected. Furthermore, nefazodone is a strong inhibitor of CYP3A4 and may increase cabazitaxel concentrations. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with nefazodone. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
260,Cabazitaxel,Nicardipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nicardipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with nicardipine. Therefore, no clinically relevant effect on nicardipine exposure is expected. Nicardipine is also a weak inhibitor of CYP3A4 and may increase concentrations of cabazitaxel, but this is unlikely to be clinically relevant.",See Summary
261,Cabazitaxel,Nicotinamide (Niacinamide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolised by xanthine oxidase and aldehyde oxidase. Cabazitaxel does not interact with this metabolic pathway.,See Summary
262,Cabazitaxel,Nifedipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nifedipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with nifedipine. Therefore, no clinically relevant effect on nifedipine exposure is expected.",See Summary
263,Cabazitaxel,Nimesulide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolised in the liver following multiple pathways including CYP2C9. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
264,Cabazitaxel,Nisoldipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nisoldipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with nisoldipine. Therefore, no clinically relevant effect on nisoldipine exposure is expected.",See Summary
265,Cabazitaxel,Nitrendipine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolised mainly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of nitrendipine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with nitrendipine. Therefore, no clinically relevant effect on nitrendipine exposure is expected.",See Summary
266,Cabazitaxel,Nitrofurantoin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolised in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug (30-40%). Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.,See Summary
267,Cabazitaxel,Norelgestromin,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolised to norgestrel (possibly by CYP3A4). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase norelgestromin concentrations. However, no clinically relevant effect on norelgestromin exposure is expected.",See Summary
268,Cabazitaxel,Norethisterone (Norethindrone),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is extensively biotransformed, first by reduction and then by sulfate and glucuronide conjugation. Cabazitaxel does not interact with this metabolic pathway.",See Summary
269,Cabazitaxel,Norgestimate,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestimate is rapidly deacetylated to the active metabolite which is further metabolised via CYP450. Cabazitaxel does not interact with this metabolic pathway.,See Summary
270,Cabazitaxel,Norgestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolized by CYP3A4 and is glucuronidated to a minor extent. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of levonorgestrel. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with levonorgestrel. Therefore, no clinically relevant effect on levonorgestrel exposure is expected.",See Summary
271,Cabazitaxel,Nortriptyline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolised mainly by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
272,Cabazitaxel,Nystatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant. Therefore, no drug interactions are expected.",See Summary
273,Cabazitaxel,Ofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is renally eliminated unchanged by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
274,Cabazitaxel,Olanzapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised mainly by CYP1A2 (major) and CYP2D6, but also by glucuronidation (UGT1A4). Cabazitaxel does not inhibit or induce CYP1A2, CYP2D6 or UGT1A4.",See Summary
275,Cabazitaxel,Olmesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine. Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.,See Summary
276,Cabazitaxel,Omeprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Omeprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase omeprazole concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on omeprazole exposure is expected. Omeprazole is also an inducer of CYP1A2 and an inhibitor of CYP2C19. Cabazitaxel is not metabolised by these CYPs.",See Summary
277,Cabazitaxel,Ondansetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolised mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Ondansetron is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase ondansetron concentrations. However, no clinically relevant effect on ondansetron exposure is expected.",See Summary
278,Cabazitaxel,Oxazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated. Cabazitaxel does not inhibit or induce UGTs.,See Summary
279,Cabazitaxel,Oxcarbazepine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is extensively metabolized to the active metabolite monohydroxyderivate (MHD) through cystolic enzymes. Cabazitaxel does not interact with this metabolic pathway. Both oxcarbazepine and MHD are inducers of CYP3A4 (moderate) and CYP3A5 and are inhibitors of CYP2C19. Oxcarbazepine and MHD may decrease cabazitaxel exposure due to CYP3A4 induction, but this is unlikely to be clinically relevant.",See Summary
280,Cabazitaxel,Oxprenolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised via glucuronidation. Cabazitaxel does not inhibit or induce UGTs.,See Summary
281,Cabazitaxel,Oxycodone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally to noroxycodone via CYP3A and oxymorphone via CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of oxycodone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with oxycodone. Therefore, no clinically relevant effect on oxycodone exposure is expected.",See Summary
282,Cabazitaxel,Paliperidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily renally eliminated (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of paliperidone. However, since CYP3A4 is a minor pathway, no clinically relevant effect on paliperidone exposure is expected.",See Summary
283,Cabazitaxel,Palonosetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Palonosetron is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Palonosetron is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of palonosetron. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with palonosetron. Therefore, no clinically relevant effect on palonosetron exposure is expected.",See Summary
284,Cabazitaxel,Pamidronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
285,Cabazitaxel,Pantoprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYPs 3A4, 2D6 and 2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase pantoprazole concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on pantoprazole exposure is expected.",See Summary
286,Cabazitaxel,Para-aminosalicylic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
287,Cabazitaxel,Paracetamol (Acetaminophen),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolised by glucuronidation (via UGTs 1A9 (major), 1A6, 1A1, and 2B15), sulfation and to a lesser extent, by oxidation (CYPs 2E1 (major), 1A2, 3A4 and 2D6). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase paracetamol concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on paracetamol exposure is expected.",See Summary
288,Cabazitaxel,Paroxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolised by CYP2D6. Paroxetine is also an inhibitor of CYP2D6 (strong) and CYP2C9. Cabazitaxel does not interact with this pathway.,See Summary
289,Cabazitaxel,Peginterferon alfa-2a,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
290,Cabazitaxel,Penicillins,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
291,Cabazitaxel,Perazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is mainly metabolised by CYPs 1A2, 3A4 and 2C19, and to a lesser extent by CYPs 2C9, 2D6 and 2E1, with oxidation via FMO3. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of perazine. However, no clinically relevant effect on perazine exposure is expected.",See Summary
292,Cabazitaxel,Periciazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
293,Cabazitaxel,Perindopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolised to other inactive metabolites. Elimination occurs predominantly via the urine. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
294,Cabazitaxel,Perphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
295,Cabazitaxel,Pethidine (Meperidine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolised mainly by CYP2B6 and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase pethidine concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on pethidine exposure is expected.",See Summary
296,Cabazitaxel,Phenelzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolised by oxidation via monoamine oxidase and to a lesser extent by acetylation. Cabazitaxel does not interact with this metabolic pathway.,See Summary
297,Cabazitaxel,Phenobarbital (Phenobarbitone),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Phenobarbital is metabolized by CYP2C19 and CYP2C9 (major pathway) and to a lesser extent by CYP2E1. Cabazitaxel does not inhibit or induce these CYPs. Phenobarbital is a strong inducer of CYPs 3A4, 2C9, 2C8 and UGTs. Cabazitaxel concentrations may decrease due to strong CYP3A4 induction. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with phenobarbital. Therefore, care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
298,Cabazitaxel,Phenprocoumon,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is mainly metabolised by CYP2C9 and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of phenprocoumon. However, no clinically relevant effect on phenprocoumon exposure is expected. ",See Summary
299,Cabazitaxel,Phenytoin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Phenytoin is mainly metabolized by CYP2C9 and to a lesser extent by CYP2C19. Cabazitaxel does not inhibit or induce CYP2C9 or CYP2C19. Phenytoin is also a strong inducer of CYP3A4, UGT and P-gp. Cabazitaxel concentrations may decrease due to CYP3A4 and P-gp induction. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with phenytoin. Therefore, care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
300,Cabazitaxel,Phytomenadione (Vitamin K),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An in vitro study found that the only CYP450 enzyme involved in phytomenadione metabolism was CYP4F2. Cabazitaxel does not inhibit or induce CYP4F2.,See Summary
301,Cabazitaxel,Pimozide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is mainly metabolised by CYP3A4 and CYP2D6 and to a lesser extent by CYP1A2. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of pimozide. However, no clinically relevant effect on pimozide exposure is expected.",See Summary
302,Cabazitaxel,Pindolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolised to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Cabazitaxel is unlikely to interfere with this metabolic or elimination pathway.,See Summary
303,Cabazitaxel,Pioglitazone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase pioglitazone concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on pioglitazone exposure is expected.",See Summary
304,Cabazitaxel,Pipotiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
305,Cabazitaxel,Piroxicam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolised by CYP2C9. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
306,Cabazitaxel,Pitavastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Pitavastatin is also a substrate of OATP1B1. Cabazitaxel does not inhibit or induce CYP2C9, CYP2C8, UGTs or OATP1B1.",See Summary
307,Cabazitaxel,Posaconazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Posaconazole is primarily metabolised by UGTs and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of posaconazole. However, no clinically relevant effect on posaconazole exposure is expected. Posaconazole is also a strong inhibitor of CYP3A4 and may increase cabazitaxel concentrations. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with posaconazole. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
308,Cabazitaxel,Potassium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is renally eliminated. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
309,Cabazitaxel,Prasugrel,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of prasugrel. However, no clinically relevant effect on prasugrel exposure is expected. ",See Summary
310,Cabazitaxel,Pravastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pravastatin is minimally metabolised via CYP enzymes and is a substrate of OATP1B1. Cabazitaxel does not inhibit or induce OATP1B1.,See Summary
311,Cabazitaxel,Prazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin is extensively metabolised, primarily by demethylation and conjugation. Cabazitaxel does not interact with this metabolic pathway.",See Summary
312,Cabazitaxel,Prednisolone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism via CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of prednisolone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with prednisolone. Therefore, no clinically relevant effect on prednisolone exposure is expected.",See Summary
313,Cabazitaxel,Prednisone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Cabazitaxel does not interact with this metabolic pathway. Prednisolone is then metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of prednisone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with prednisone. Therefore, no clinically relevant effect on prednisone exposure is expected.",See Summary
314,Cabazitaxel,Pregabalin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pregabalin is cleared mainly by glomerular filtration (90% as unchanged drug). Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
315,Cabazitaxel,Prochlorperazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Cabazitaxel does not inhibit or induce CYP2D6 or CYP2C19.,See Summary
316,Cabazitaxel,Promethazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolised by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
317,Cabazitaxel,Propafenone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of propafenone. However, since CYP3A4 is a minor pathway, no clinically relevant effect on propafenone exposure is expected.",See Summary
318,Cabazitaxel,Propranolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolised by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Cabazitaxel does not inhibit or induce these CYPs or UGTs.",See Summary
319,Cabazitaxel,Prucalopride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly renally eliminated, partly by active secretion by renal transporters. Prucalopride is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of prucalopride. However, no clinically relevant effect on prucalopride exposure is expected.",See Summary
320,Cabazitaxel,Pyrazinamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolised by xanthine oxidase. Cabazitaxel does not interact with this metabolic pathway.,See Summary
321,Cabazitaxel,Pyridoxine (Vitamin B6),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
322,Cabazitaxel,Quetiapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase quetiapine concentrations. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with quetiapine. Therefore, no clinically relevant effect on quetiapine exposure is expected.",See Summary
323,Cabazitaxel,Quinapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Cabazitaxel does not interact with this metabolic or elimination pathway.,See Summary
324,Cabazitaxel,Quinidine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Quinidine is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2E1. Quinidine is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of quinidine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with quinidine. Therefore, no clinically relevant effect on quinidine exposure is expected. Quinidine is also an inhibitor of CYP2D6 (strong), CYP3A4 (weak) and P-gp (moderate). Cabazitaxel concentrations may increase due to weak CYP3A4 inhibition and moderate P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring for cabazitaxel toxicity may be required.",See Summary
325,Cabazitaxel,Rabeprazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolised via non-enzymatic reduction and to a lesser extent by CYP2C19 and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase rabeprazole concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on rabeprazole exposure is expected.",See Summary
326,Cabazitaxel,Ramipril,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolised to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Cabazitaxel does not interact with this metabolic pathway.",See Summary
327,Cabazitaxel,Ranitidine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via OAT1/OAT3. Cabazitaxel does not inhibit or induce OATs.,See Summary
328,Cabazitaxel,Ranolazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Ranolazine is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Ranolazine is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of ranolazine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ranolazine. Therefore, no clinically relevant effect on ranolazine exposure is expected. Moreover, ranolazine is a weak inhibitor of P-gp, CYP3A4 and CYP2D6. Cabazitaxel concentrations may increase due to P-gp and CYP3A4 inhibition. As the clinical relevance of this interaction is unknown, monitoring for cabazitaxel toxicity may be required.",See Summary
329,Cabazitaxel,Reboxetine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of reboxetine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with reboxetine. Therefore, no clinically relevant effect on reboxetine exposure is expected. In vitro data indicate reboxetine to be a weak inhibitor of CYP3A4 but in vivo data showed no inhibitory effect on CYP3A4. No clinically relevant effect on cabazitaxel exposure is expected.",See Summary
330,Cabazitaxel,Repaglinide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolised by CYP2C8 and CYP3A4, with clinical data indicating it is a substrate of the hepatic transporter OATP1B1. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase repaglinide concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on nateglinide exposure is expected.",See Summary
331,Cabazitaxel,Retinol (Vitamin A),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver but retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Cabazitaxel does not interact with this metabolic pathway.",See Summary
332,Cabazitaxel,Riboflavin (Vitamin B2),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
333,Cabazitaxel,Rifabutin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Rifabutin is metabolised by CYP3A4 and via deacetylation. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of rifabutin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with rifabutin. Therefore, no clinically relevant effect on rifabutin exposure is expected. Rifabutin is also a strong CYP3A4 and P-gp inducer and may decrease concentrations of cabazitaxel. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with rifabutin. Care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
334,Cabazitaxel,Rifampicin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Rifampicin is metabolised via deacetylation. Cabazitaxel does not interact with this metabolic pathway. Rifampicin is also a strong CYP3A4 and P-gp inducer. In patients, coadministration of cabazitaxel and rifampicin decreased cabazitaxel AUC by 17%. Therefore, care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
335,Cabazitaxel,Rifapentine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Rifapentine is metabolised via deacetylation. Cabazitaxel does not interact with this metabolic pathway. Rifapentine is also a strong CYP3A4, CYP2C8 and P-gp inducer. Concentrations of cabazitaxel may decrease due to CYP3A4 and P-gp induction. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with rifapentine. Therefore, care should be taken. No a priori dose adjustment is necessary, but monitoring of cabazitaxel efficacy may be required.",See Summary
336,Cabazitaxel,Rifaximin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug. Cabazitaxel is unlikely to interfere with this elimination pathway.",See Summary
337,Cabazitaxel,Risperidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Risperidone is also a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of risperidone. However, no clinically relevant effect on risperidone exposure is expected.",See Summary
338,Cabazitaxel,Rivaroxaban,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Rivaroxaban is partly metabolised in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine. Rivaroxaban is also a substrate of P-gp and BCRP. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of rivaroxaban. However, no clinically relevant effect on rivaroxaban exposure is expected",See Summary
339,Cabazitaxel,Rosiglitazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP2C9. Cabazitaxel does not inhibit or induce CYP2C8 or CYP2C9.,See Summary
340,Cabazitaxel,Rosuvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosuvastatin is largely excreted unchanged in the faeces via OATP1B1 and is a substrate of BCRP. Cabazitaxel does not inhibit or induce OATP1B1 or BCRP.,See Summary
341,Cabazitaxel,Salbutamol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolised to the inactive salbutamol-4’-O-sulphate. Cabazitaxel does not interact with this metabolic pathway.,See Summary
342,Cabazitaxel,Salmeterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase salmeterol concentrations. However, since the systemic exposure of salmeterol is low, no clinically relevant effect on salmeterol exposure is expected.",See Summary
343,Cabazitaxel,Saxagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolised by CYP3A4 and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of saxagliptin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with saxagliptin. Therefore, no clinically relevant effect on saxagliptin exposure is expected.",See Summary
344,Cabazitaxel,Senna,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. No clinically significant interactions are known.,See Summary
345,Cabazitaxel,Sertindole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertindole is metabolised by CYP2D6 and CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of sertindole. However, no clinically relevant effect on sertindole exposure is expected.",See Summary
346,Cabazitaxel,Sertraline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolised by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of sertraline. However, since CYP3A4 is a minor pathway, no clinically relevant effect on sertraline exposure is expected.",See Summary
347,Cabazitaxel,Sildenafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of sildenafil. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with sildenafil. Therefore, no clinically relevant effect on sildenafil exposure is expected.",See Summary
348,Cabazitaxel,Simvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolised by CYP3A4. Simvastatin is also a substrate of BCRP and the active metabolite is a substrate of OATP1B1. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of simvastatin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with simvastatin. Therefore, no clinically relevant effect on simvastatin exposure is expected.",See Summary
349,Cabazitaxel,Sirolimus,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sirolimus is metabolised by CYP3A4 and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of sirolimus. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with sirolimus. Therefore, no clinically relevant effect on sirolimus exposure is expected. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
350,Cabazitaxel,Sitagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, and P-gp) and metabolism by CYP3A4 represents a minor metabolic pathway. Cabazitaxel is an in vitro inhibitor of P-gp and CYP3A4 and may increase sitagliptin concentrations. However, no clinically relevant effect on sitagliptin exposure is expected.",See Summary
351,Cabazitaxel,Sodium nitroprusside,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. Cabazitaxel does not interact with this metabolic pathway.",See Summary
352,Cabazitaxel,Sotalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sotalol is excreted unchanged via renal elimination. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
353,Cabazitaxel,Spectinomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
354,Cabazitaxel,Spironolactone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolised by the flavin containing monooxygenases. Cabazitaxel does not interact with this metabolic pathway.,See Summary
355,Cabazitaxel,Stanozolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Stanozolol undergoes hepatic metabolism. Cabazitaxel does not interact with this metabolic pathway.,See Summary
356,Cabazitaxel,St John's Wort,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. St John’s wort is a P-gp and CYP3A4 inducer and may decrease cabazitaxel concentrations. In patients, coadministration of cabazitaxel and the strong CYP3A4 inducer, rifampicin, decreased cabazitaxel AUC by 17%. A similar effect may occur after coadministration with St John’s Wort. If coadministration is clinically necessary, closely monitor cabazitaxel efficacy.",See Summary
357,Cabazitaxel,Streptokinase,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Cabazitaxel does not interact with this metabolic pathway.",See Summary
358,Cabazitaxel,Streptomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is eliminated by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
359,Cabazitaxel,Sulfadiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Cabazitaxel does not inhibit or induce CYP2C9.,See Summary
360,Cabazitaxel,Sulpiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
361,Cabazitaxel,Tacrolimus,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tacrolimus is metabolised mainly by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of tacrolimus. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with tacrolimus. Therefore, no clinically relevant effect on tacrolimus exposure is expected. Tacrolimus is also an inhibitor of CYP3A4 and OATP1B1 in vitro but produced modest inhibition of CYP3A4 and OATP1B1 in the range of clinical concentrations. No clinically relevant effect on cabazitaxel exposure due to CYP3A4 and OATP1B1 inhibition is expected. Due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered.",See Summary
362,Cabazitaxel,Tadalafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of tadalafil. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with tadalafil. Therefore, no clinically relevant effect on tadalafil exposure is expected.",See Summary
363,Cabazitaxel,Tamsulosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of tamsulosin. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with tamsulosin. Therefore, no clinically relevant effect on tamsulosin exposure is expected.",See Summary
364,Cabazitaxel,Tazobactam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is excreted as unchanged drug (approximately 80%) and inactive metabolite (approximately 20%) in the urine. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
365,Cabazitaxel,Telithromycin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Telithromycin is metabolised by CYP3A4 (50%) with the remaining 50% metabolised via non-CYP mediated pathways. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of telithromycin. However, no clinically relevant effect on telithromycin exposure is expected. Furthermore, telithromycin is an inhibitor of CYP3A4 (strong) and P-gp, but the clinical relevance of P-gp inhibition is unknown. Cabazitaxel concentrations may increase due to CYP3A4 and P-gp inhibition. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with telithromycin. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
366,Cabazitaxel,Telmisartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Cabazitaxel does not inhibit or induce UGTs.,See Summary
367,Cabazitaxel,Temazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Cabazitaxel does not inhibit or induce UGTs.,See Summary
368,Cabazitaxel,Terbinafine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolised by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYP2C8 and CYP2C19. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase terbinafine concentrations. However, no clinically relevant effect on terbinafine exposure is expected. Furthermore, terbinafine is also a moderate-strong inhibitor of CYP2D6. Cabazitaxel is not metabolised by CYP2D6.",See Summary
369,Cabazitaxel,Testosterone,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of testosterone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with testosterone. Therefore, no clinically relevant effect on testosterone exposure is expected.",See Summary
370,Cabazitaxel,Tetracycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracycline is eliminated unchanged primarily by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
371,Cabazitaxel,Theophylline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolised by CYP1A2. Cabazitaxel does not inhibit or induce CYP1A2.,See Summary
372,Cabazitaxel,Thiamine (Vitamin B1),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
373,Cabazitaxel,Thioridazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of thioridazine. However, since CYP3A4 is a minor pathway, no clinically relevant effect on thioridazine exposure is expected.",See Summary
374,Cabazitaxel,Tiapride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiapride is excreted largely unchanged in urine. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
375,Cabazitaxel,Ticagrelor,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor is a substrate of CYP3A4 and P-gp. Cabazitaxel is an in vitro inhibitor of CYP3A4 and P-gp and may increase concentrations of ticagrelor. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ticagrelor. Therefore, no clinically relevant effect on ticagrelor exposure is expected. Furthermore, ticagrelor is a mild inhibitor of CYP3A4 and may increase cabazitaxel concentrations, but this is unlikely to be clinically relevant.",See Summary
376,Cabazitaxel,Timolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
377,Cabazitaxel,Tinzaparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is renally excreted as unchanged or almost unchanged drug. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
378,Cabazitaxel,Tolbutamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolised by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Cabazitaxel does not inhibit or induce these CYPs.,See Summary
379,Cabazitaxel,Tolterodine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 playing a minor role. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase tolterodine concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on tolterodine exposure is expected.",See Summary
380,Cabazitaxel,Torasemide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolised mainly by CYP2C9. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Cabazitaxel does not inhibit or induce CYP2C9 or OATs.",See Summary
381,Cabazitaxel,Tramadol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolised by CYPs 3A4, 2B6, and 2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of tramadol. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with tramadol. Therefore, no clinically relevant effect on tramadol exposure is expected.",See Summary
382,Cabazitaxel,Trandolapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat. Cabazitaxel does not interact with this metabolic pathway.,See Summary
383,Cabazitaxel,Tranexamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranexamic acid is mainly cleared by glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
384,Cabazitaxel,Tranylcypromine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Cabazitaxel does not interact with this metabolic pathway.,See Summary
385,Cabazitaxel,Trazodone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of trazodone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with trazodone. Therefore, no clinically relevant effect on trazodone exposure is expected.",See Summary
386,Cabazitaxel,Triamcinolone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of triamcinolone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with triamcinolone. Therefore, no clinically relevant effect on triamcinolone exposure is expected.",See Summary
387,Cabazitaxel,Triazolam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolised by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of triazolam. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with triazolam. Therefore, no clinically relevant effect on triazolam exposure is expected.",See Summary
388,Cabazitaxel,Trimethoprim/Sulfamethoxazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. Cabazitaxel is unlikely to interfere with the elimination of trimethoprim. To a lesser extent (approximately 30%) trimethoprim is metabolised by CYP enzymes (in vitro data suggest CYPs 3A4, 1A2 and 2C9). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase trimethoprim concentrations, but since CYP3A4 is a minor pathway, no clinically relevant effect on trimethoprim exposure is expected. Trimethoprim is also a weak CYP2C8 inhibitor and in vitro data suggest that trimethoprim is an inhibitor of OCT2 and MATE1. Sulfamethoxazole is metabolised by, and is a weak inhibitor of, CYP2C9. Cabazitaxel does not interact with these pathways.",See Summary
389,Cabazitaxel,Trimipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolised mainly by CYP2D6. Cabazitaxel does not inhibit or induce CYP2D6.,See Summary
390,Cabazitaxel,Tropisetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tropisetron is metabolised mainly by CYP2D6 and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of tropisetron. However, no clinically relevant effect on tropisetron exposure is expected.",See Summary
391,Cabazitaxel,Ulipristal,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if cabazitaxel is used for treatment of hormone-sensitive cancer. If used for hormone-insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of ulipristal. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with ulipristal. Therefore, no clinically relevant effect on ulipristal exposure is expected.",See Summary
392,Cabazitaxel,Valproic acid (Valproate),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproic acid is primarily metabolized by glucuronidation (50%) and mitochondrial beta-oxidation (30-40%). To a lesser extent (10%) valproic acid is metabolized by CYP2C9 and CYP2C19. Valproic acid is an inhibitor of CYP2C9. Cabazitaxel does not interact with this pathway.,See Summary
393,Cabazitaxel,Valsartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is eliminated unchanged mostly through biliary excretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
394,Cabazitaxel,Vancomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via glomerular filtration. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
395,Cabazitaxel,Venlafaxine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of venlafaxine. However, since CYP3A4 is a minor pathway, no clinically relevant effect on venlafaxine exposure is expected.",See Summary
396,Cabazitaxel,Verapamil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Verapamil is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8 and 2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of verapamil. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with verapamil. Therefore, no clinically relevant effect on verapamil exposure is expected. Verapamil is also a moderate inhibitor of CYP3A4 and may increase concentrations of cabazitaxel, but a clinically relevant effect on cabazitaxel exposure is not expected. In patients, coadministration with aprepitant, a moderate CYP3A4 inhibitor during the first three days of administration, did not affect cabazitaxel exposure. A similar effect may occur after coadministration with verapamil.",See Summary
397,Cabazitaxel,Vildagliptin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vildagliptin is inactivated via non-CYP mediated hydrolysis and is a substrate of P-gp. Cabazitaxel is an in vitro inhibitor of P-gp and may increase concentrations of vildagliptin. However, no clinically relevant effect on vildagliptin exposure is expected.",See Summary
398,Cabazitaxel,Vitamin E,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
399,Cabazitaxel,Voriconazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Voriconazole is metabolised by CYP2C19 (major) and to a lesser extent by CYP3A4 and CYP2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase voriconazole concentrations. However, no clinically relevant effect on voriconazole exposure is expected. Voriconazole is also a strong inhibitor of CYP3A4 and a weak inhibitor of CYPs 2C9, 2C19 and 2B6. Cabazitaxel concentrations may increase due to strong CYP3A4 inhibition. Coadministration with ketoconazole, a strong CYP3A4 inhibitor, increased cabazitaxel exposure by 25%. A similar effect may occur after coadministration with voriconazole. Care should be taken. Monitoring for cabazitaxel toxicity should be considered. A dose reduction of up to 25% may be required.",See Summary
400,Cabazitaxel,Warfarin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and CYP3A4. S-warfarin (more potent) is metabolised by CYP2C9. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of warfarin. However, no clinically relevant effect on warfarin exposure is expected.",See Summary
401,Cabazitaxel,Xipamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Cabazitaxel does not interact with this metabolic or elimination pathway.",See Summary
402,Cabazitaxel,Zaleplon,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolised by aldehyde oxidase and to a lesser extent by CYP3A4. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase zaleplon concentrations. However, since CYP3A4 is a minor pathway, no clinically relevant effect on zaleplon exposure is expected.",See Summary
403,Cabazitaxel,Ziprasidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of ziprasidone. However, since CYP3A4 is a minor pathway, no clinically relevant effect on ziprasidone exposure is expected.",See Summary
404,Cabazitaxel,Zoledronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zoledronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Cabazitaxel is unlikely to interfere with this elimination pathway.,See Summary
405,Cabazitaxel,Zolpidem,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 1A2. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of zolpidem. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with zolpidem. Therefore, no clinically relevant effect on zolpidem exposure is expected.",See Summary
406,Cabazitaxel,Zopiclone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C8. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of zopiclone. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with zopiclone. Therefore, no clinically relevant effect on zopiclone exposure is expected.",See Summary
407,Cabazitaxel,Zotepine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of zotepine. However, coadministration of cabazitaxel with midazolam, a CYP3A4 probe substrate, did not alter midazolam exposure to a clinically relevant extent (AUClast increased by 4%). A similar effect may occur with zotepine. Therefore, no clinically relevant effect on zotepine exposure is expected.",See Summary
408,Cabazitaxel,Zuclopenthixol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolised by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. Cabazitaxel is an in vitro inhibitor of CYP3A4 and may increase concentrations of zuclopenthixol. However, no clinically relevant effect on zuclopenthixol exposure is expected.",See Summary
